Wire Stories
-
441Cannabis consumer spending tightens, highlighting importance of brand strength
Consumer spending on cannabis roughly flat YOY over Labor Day weekend, a historic Top 5 Cannabis Spending holiday DENVER, Sept. 12, 2022...
-
452ARKO Corp. Announces Agreement to Acquire all Assets of Transit Energy Group, a Large Privately Held Portfolio in the Southeast with Approximately 350 Sites Across Retail and Wholesale
ARKO continues to work to create value for stockholders and execute its growth strategy, entering into an agreement for the accretive acquisition...
-
452BIO-key and Multipoint GROUP Join Forces to Promote Cybersecurity and Identity Solutions to High-Growth Global Markets in Europe and the Middle East
Partnership includes distribution, pre-sales, training, and full support to resellers and customers WALL, N.J. and MADRID, Spain, Sept. 12, 2022 (GLOBE NEWSWIRE)...
-
587Spaceflight Inc. Taps Global Launch Vehicle Portfolio to Take Fast-Growing Astrocast IoT Constellation to Orbit
Indian Polar Satellite Launch Vehicle (PSLV) to launch the four nanosatellites in October 2022 under commercial arrangement with NewSpace India Limited (NSIL),...
-
517CogniSaaS: Bringing Customer-Centricity to B2B SaaS
BANGALORE, India–(BUSINESS WIRE)–#B2B–Last year B2B SaaS companies lost over $15 Billion in ARR (Annual Recurring Revenue) from customer churn and it is...
-
408Vontobel continues multi-boutique expansion in North America
� NEW YORK–(BUSINESS WIRE)–With growing demand from US and Canadian investors for systematic and fundamental investing, Vontobel has made available select strategies...
-
589Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV� (enfortumab vedotin-ejfv) with KEYTRUDA� (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer
� Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab � �...
-
469AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug Designation in Korea for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer
NEW YORK & SEOUL, South Korea–(BUSINESS WIRE)–#BTD—AnHeart Therapeutics and NewG Lab Therapeutics, a subsidiary of NewG Lab Pharma, announced that the Ministry...
-
531Bacardi Announces New Leadership for Its Global Travel Retail Business
HAMILTON, Bermuda–(BUSINESS WIRE)–#BacardiLife–Bacardi announces a change at the top of its global travel retail business (GTR), effective January 2023. The current Managing...
-
419Vista Gold Corp. Provides Update on Strategic Process
DENVER–(BUSINESS WIRE)–Vista Gold Corp. (NYSE American and TSX: VGZ) (�Vista� or the �Company�) today announced the following update regarding the Company�s process...
